Considering the various health problems associated with obesity in dogs, including renal diseases, joint disorders, and skin diseases, effective management strategies and guidelines are urgently needed. This situation has led to a growing demand for veterinary medications aimed at addressing obesity in dogs. However, the field faces a significant hurdle due to the absence of standardized guidelines for assessing the effectiveness of these anti-obesity medications in dogs. In response to this gap, the Animal and Plant Quarantine Agency (APQA) in Korea has made a crucial step by introducing clinical trial guidelines to evaluate the efficacy of treatments for canine obesity, specifically aimed at approving veterinary medicinal products. The guidelines outlined the selection criteria for target dogs, highlighting the importance of consistency within the control and treated groups. Treatment efficacy is subsequently evaluated by physical examination, body fat reduction, and biochemical indicators. In addition, the guidelines cover dosage and administration, monitoring after dosing, and statistical analysis. By doing so, this guideline not only highlights the significance of the APQA’s initiative in improving the care of obese dogs but also provides practical insights to enhance the standardization and effectiveness of clinical trials in veterinary medicine.

Drug-induced liver injury (DILI) is considered to be a significant cause of drug wastage. To mitigate clinical DILI risks, assessing drugs using human liver models is crucial since animal studies may fall short due to species-specific liver pathway variations. Cell-based preclinical hepatotoxicity testing is often pertinent. In the present study, cells from a human liver cancer line (HepG2 and HepaRG) were cultured in both formats of 2D and 3D spheroids to explore their responses to drugs. Liver-specific marker expressions across cell lines and culture formats were also examined to assess disparities in DILI marker expressions. After treating each cell with the drugs, cytotoxicity and liver injury markers aspartate aminotransferase and alanine aminotransferase were increased. In addition, liver specific markers albumin and urea decreased in a drug concentration-dependent manner. These findings were consistent with drug sensitivity. Additionally, mRNA expression levels of cytochrome P450 enzymes (CYPs) involved in hepatocellular drug metabolism were compared following treatment with enzyme inducers. CYP1A2 and CYP2C9 were not epxressed in HepG2 cells. HepaRG cells exhibited significantly increased expression of CYP1A2, 2C9, and 3A4 post-treatment. Notably, enzyme expression was notably higher in 3D cultures than in 2D cultures. Collectively, these findings suggest that HepaRG cells and 3D cultures hold promise for evaluating DILI during early-stage drug development.

One hundred one enterococcal isolates from feces of livestock animals in Korea were screened for the presence of bacteriocins. Sixteen of 41 (39%) E. faecalis and 4 of 56 (7.1%) E. faecium isolates showed antimicrobial activity against at least one indicator strain. Only 4 of 20 the enterococcal isolates showing antimicrobial activity possessed at least one bacteriocin gene. While entA and entB were detected in three isolates as a pair of genotype, entQ, bac31, and AS-48 were not found in the enterococcal isolates. In almost all isolates, a correlation between genotype and phenotype of these determinants was not always observed.